Search

Your search keyword '"Avadhani, Radhika"' showing total 136 results
Start Over Author "Avadhani, Radhika" Publication Year Range Last 50 years
136 results on '"Avadhani, Radhika"'

8. Abstract TMP74: Association Between Hematoma Volume After Risk of Subsequent Ischemic Stroke: A MISTIE III and ATACH-2 Analysis

Author

Harris, William, primary, Kaiser, Jed, additional, Avadhani, Radhika, additional, Iadecola, Costantino, additional, Sheth, Kevin N, additional, Awad, Issam, additional, Goldstein, Joshua N, additional, Qureshi, Adnan I, additional, Hanley, Daniel F, additional, Kamel, Hooman, additional, Ziai, Wendy C, additional, and Murthy, Santosh B, additional

Published
2024
Full Text
View/download PDF

11. Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III Trials

Author

Magid-Bernstein, Jessica R, Li, Yunke, Cho, Sung-Min, Piran, Pirouz J., Roh, David J., Gupta, Ajay, Shoamanesh, Ashkan, Merkler, Alexander, Zhang, Cenai, Avadhani, Radhika, Montano, Nataly, Iadecola, Constantino, Falcone, Guido, Sheth, Kevin, Qureshi, Adnan, Rosand, Jonathan, Goldstein, Joshua, Awad, Issam, Hanley, Daniel, Kamel, Hooman, Ziai, Wendy C., and Murthy, Santosh B.

Published
2021
Full Text
View/download PDF

12. Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis

Author

Miller, Jena L., primary, Baschat, Ahmet A., additional, Rosner, Mara, additional, Blumenfeld, Yair J., additional, Moldenhauer, Julie S., additional, Johnson, Anthony, additional, Schenone, Mauro H., additional, Zaretsky, Michael V., additional, Chmait, Ramen H., additional, Gonzalez, Juan M., additional, Miller, Russell S., additional, Moon-Grady, Anita J., additional, Bendel-Stenzel, Ellen, additional, Keiser, Amaris M., additional, Avadhani, Radhika, additional, Jelin, Angie C., additional, Davis, Jonathan M., additional, Warren, Daniel S., additional, Hanley, Daniel F., additional, Watkins, Joslynn A., additional, Samuels, Joshua, additional, Sugarman, Jeremy, additional, and Atkinson, Meredith A., additional

Published
2023
Full Text
View/download PDF

13. Cerebral small vessel disease modifies outcomes after minimally invasive surgery for intracerebral haemorrhage

Author

Li, Yunke, primary, Cho, Sung-Min, additional, Avadhani, Radhika, additional, Ali, Hassan, additional, Hao, Yi, additional, Murthy, Santosh B, additional, Goldstein, Joshua N, additional, Xia, Fan, additional, Hu, Xin, additional, Ullman, Natalie L, additional, Awad, Issam, additional, Hanley, Daniel, additional, and Ziai, Wendy C, additional

Published
2023
Full Text
View/download PDF

16. Catheter Tract Hemorrhages and Intracerebral Hemorrhage Outcomes in the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Trial

Author

Garton, Andrew L. A., primary, Oh, Stephanie E., additional, Müller, Achim, additional, Avadhani, Radhika, additional, Zhang, Cenai, additional, Merkler, Alexander E., additional, Awad, Issam, additional, Hanley, Daniel, additional, Kamel, Hooman, additional, Ziai, Wendy C., additional, and Murthy, Santosh B., additional

Published
2023
Full Text
View/download PDF

18. Dexmedetomidine Opioid Sparing Effect in Mechanically Ventilated Children (DOSE): Trial of Fentanyl versus Fentanyl + Dexmedetomidine for Maintenance of Sedation

Author

Becker, Mara L., additional, Fischer, Gwenyth, additional, Hornik, Chi D., additional, Alibrahim, Omar, additional, Iheagwara, Kelechi, additional, Abulebda, Kamal, additional, Bass, Andora L., additional, Irby, Katherine, additional, Subbaswamy, Anjali, additional, Zivick, Elizabeth E., additional, Sweney, Jill, additional, Stormorken, Anne G., additional, Barker, Erin E., additional, Mahadaveiah, Shruthi, additional, Lutfi, Riad, additional, McCrory, Michael C., additional, Costello, John M., additional, Ackerman, Kate G., additional, Munoz-Pareja, Jennifer C., additional, Feger, Bryan J., additional, Dean, J. Michael, additional, Hanley, Daniel F., additional, Greenberg, Rachel G., additional, Avadhani, Radhika, additional, Thompson, Richard E., additional, Benjamin, Daniel K., additional, Hornik, Christoph P., additional, and Zimmerman, Kanecia O., additional

Published
2023
Full Text
View/download PDF

19. Abstract WP121: Can The Extended Glasgow Outcome Scale (e-gos) Augment The Interpretation Of Results From Clinical Trials Of Minimally Invasive Surgery Of Spontaneous Intracerebral Hemorrhage Using The Modified Rankin Scale (mrs): A Secondary Analysis Of The Clear-iii And Mistie-iii Trials

Author

Sun, Philip Y, primary, Thompson, Richard, additional, Akindahunsi, Taiwo, additional, Avadhani, Radhika, additional, Nyquist, Paul A, additional, Awad, Issam A, additional, Hanley, Daniel F, additional, and Ziai, Wendy C, additional

Published
2023
Full Text
View/download PDF

20. Abstract TP121: Association Between Neutrophil-lymphocyte Ratio And 30-day Infection And Thrombotic Outcomes After Intracerebral Hemorrhage: A CLEAR III Analysis

Author

Kaleem, Safa, primary, Gusdon, Aaron, additional, Oh, Stephanie, additional, Merkler, Alexander E, additional, Avadhani, Radhika, additional, Awad, Issam A, additional, Hanley, Daniel F, additional, Kamel, Hooman, additional, Ziai, Wendy C, additional, and Murthy, Santosh, additional

Published
2023
Full Text
View/download PDF

21. Neonatal survival after serial amnioinfusions for fetal bilateral renal agenesis: report from the raft trial

Author

Miller, Jena L., primary, Baschat, Ahmet A., additional, Rosner, Mara, additional, Blumenfeld, Yair J., additional, Moldenhauer, Julie, additional, Johnson, Anthony, additional, Schenone, Mauro, additional, Zaretsky, Michael V., additional, Chmait, Ramen H., additional, Velez, Juan Gonzalez, additional, Miller, Russell S., additional, Moon-Grady, Anita J., additional, Bendel-Stenzel, Ellen M., additional, Keiser, Amaris, additional, Avadhani, Radhika, additional, Jelin, Angie, additional, Davis, Jonathan, additional, Warren, Daniel, additional, Hanley, Daniel, additional, and Atkinson, Meredith, additional

Published
2023
Full Text
View/download PDF

23. One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability

Author

Shah, Vishank A., primary, Thompson, Richard E., additional, Yenokyan, Gayane, additional, Acosta, Julian N., additional, Avadhani, Radhika, additional, Dlugash, Rachel, additional, McBee, Nichol, additional, Li, Yunke, additional, Hansen, Bjorn M., additional, Ullman, Natalie, additional, Falcone, Guido, additional, Awad, Issam A., additional, Hanley, Daniel F., additional, and Ziai, Wendy C., additional

Published
2022
Full Text
View/download PDF

24. Association of Intraventricular Fibrinolysis With Clinical Outcomes in Intracerebral Hemorrhage: An Individual Participant Data Meta-Analysis

Author

Kuramatsu, Joji B., primary, Gerner, Stefan T., additional, Ziai, Wendy, additional, Bardutzky, Jürgen, additional, Sembill, Jochen A., additional, Sprügel, Maximilian I., additional, Mrochen, Anne, additional, Kölbl, Kathrin, additional, Ram, Malathi, additional, Avadhani, Radhika, additional, Falcone, Guido J., additional, Selim, Magdy H., additional, Lioutas, Vasileios-Arsenios, additional, Endres, Matthias, additional, Zweynert, Sarah, additional, Vajkoczy, Peter, additional, Ringleb, Peter A., additional, Purrucker, Jan C., additional, Volkmann, Jens, additional, Neugebauer, Hermann, additional, Erbguth, Frank, additional, Schellinger, Peter D., additional, Knappe, Ulrich J., additional, Fink, Gereon R., additional, Dohmen, Christian, additional, Minnerup, Jens, additional, Reichmann, Heinz, additional, Schneider, Hauke, additional, Röther, Joachim, additional, Reimann, Gernot, additional, Schwarz, Michael, additional, Bäzner, Hansjörg, additional, Claßen, Joseph, additional, Michalski, Dominik, additional, Witte, Otto W., additional, Günther, Albrecht, additional, Hamann, Gerhard F., additional, Lücking, Hannes, additional, Dörfler, Arnd, additional, Ishfaq, Muhammad Fawad, additional, Chang, Jason J., additional, Testai, Fernando D., additional, Woo, Daniel, additional, Alexandrov, Andrei V., additional, Staykov, Dimitre, additional, Goyal, Nitin, additional, Tsivgoulis, Georgios, additional, Sheth, Kevin N., additional, Awad, Issam A., additional, Schwab, Stefan, additional, Hanley, Daniel F., additional, Huttner, Hagen B., additional, Sansing, Lauren, additional, Matouk, Charles C., additional, Leasure, Audrey, additional, Sobesky, Jan, additional, Bauer, Miriam, additional, Schurig, Johannes, additional, Rizos, Timolaos, additional, Haeusler, Karl Georg, additional, Müllges, Wolfgang, additional, Kraft, Peter, additional, Schubert, Anna-Lena, additional, Stösser, Sebastian, additional, Ludolph, Albert Christian, additional, Nueckel, Martin, additional, Glahn, Jörg, additional, Stetefeld, Henning, additional, Rahmig, Jan, additional, Fisse, Anna Lena, additional, Michels, Peter, additional, Schwert, Henning, additional, Hagemann, Georg, additional, Rakers, Florian, additional, Wöhrle, Johannes C., additional, Alshammari, Fahid, additional, Horn, Markus, additional, Bahner, Dirk, additional, Urbanek, Christian, additional, Palm, Frederick, additional, and Grau, Armin, additional

Published
2022
Full Text
View/download PDF

26. Association of Intraventricular Fibrinolysis With Clinical Outcomes in Intracerebral Hemorrhage: An Individual Participant Data Meta-Analysis

Author

Kuramatsu, Joji B., Gerner, Stefan T., Ziai, Wendy, Bardutzky, Juergen, Sembill, Jochen A., Spruegel, Maximilian, I, Mrochen, Anne, Koelbl, Kathrin, Ram, Malathi, Avadhani, Radhika, Falcone, Guido J., Selim, Magdy H., Lioutas, Vasileios-Arsenios, Endres, Matthias, Zweynert, Sarah, Vajkoczy, Peter, Ringleb, Peter A., Purrucker, Jan C., Volkmann, Jens, Neugebauer, Hermann, Erbguth, Frank, Schellinger, Peter D., Knappe, Ulrich J., Fink, Gereon R., Dohmen, Christian, Minnerup, Jens, Reichmann, Heinz, Schneider, Hauke, Roether, Joachim, Reimann, Gernot, Schwarz, Michael, Baezner, Hansjoerg, Classen, Joseph, Michalski, Dominik, Witte, Otto W., Guenther, Albrecht, Hamann, Gerhard F., Luecking, Hannes, Doerfler, Arnd, Ishfaq, Muhammad Fawad, Chang, Jason J., Testai, Fernando D., Woo, Daniel, Alexandrov, Andrei, V, Staykov, Dimitre, Goyal, Nitin, Tsivgoulis, Georgios, Sheth, Kevin N., Awad, Issam A., Schwab, Stefan, Hanley, Daniel F., Huttner, Hagen B., Kuramatsu, Joji B., Gerner, Stefan T., Ziai, Wendy, Bardutzky, Juergen, Sembill, Jochen A., Spruegel, Maximilian, I, Mrochen, Anne, Koelbl, Kathrin, Ram, Malathi, Avadhani, Radhika, Falcone, Guido J., Selim, Magdy H., Lioutas, Vasileios-Arsenios, Endres, Matthias, Zweynert, Sarah, Vajkoczy, Peter, Ringleb, Peter A., Purrucker, Jan C., Volkmann, Jens, Neugebauer, Hermann, Erbguth, Frank, Schellinger, Peter D., Knappe, Ulrich J., Fink, Gereon R., Dohmen, Christian, Minnerup, Jens, Reichmann, Heinz, Schneider, Hauke, Roether, Joachim, Reimann, Gernot, Schwarz, Michael, Baezner, Hansjoerg, Classen, Joseph, Michalski, Dominik, Witte, Otto W., Guenther, Albrecht, Hamann, Gerhard F., Luecking, Hannes, Doerfler, Arnd, Ishfaq, Muhammad Fawad, Chang, Jason J., Testai, Fernando D., Woo, Daniel, Alexandrov, Andrei, V, Staykov, Dimitre, Goyal, Nitin, Tsivgoulis, Georgios, Sheth, Kevin N., Awad, Issam A., Schwab, Stefan, Hanley, Daniel F., and Huttner, Hagen B.

Abstract

Background: In patients with intracerebral hemorrhage (ICH), the presence of intraventricular hemorrhage constitutes a promising therapeutic target. Intraventricular fibrinolysis (IVF) reduces mortality, yet impact on functional disability remains unclear. Thus, we aimed to determine the influence of IVF on functional outcomes. Methods: This individual participant data meta-analysis pooled 1501 patients from 2 randomized trials and 7 observational studies enrolled during 2004 to 2015. We compared IVF versus standard of care (including placebo) in patients treated with external ventricular drainage due to acute hydrocephalus caused by ICH with intraventricular hemorrhage. The primary outcome was functional disability evaluated by the modified Rankin Scale (mRS; range: 0-6, lower scores indicating less disability) at 6 months, dichotomized into mRS score: 0 to 3 versus mRS: 4 to 6. Secondary outcomes included ordinal-shift analysis, all-cause mortality, and intracranial adverse events. Confounding and bias were adjusted by random effects and doubly robust models to calculate odds ratios and absolute treatment effects (ATE). Results: Comparing treatment of 596 with IVF to 905 with standard of care resulted in an ATE to achieve the primary outcome of 9.3% (95% CI, 4.4-14.1). IVF treatment showed a significant shift towards improved outcome across the entire range of mRS estimates, common odds ratio, 1.75 (95% CI, 1.39-2.17), reduced mortality, odds ratio, 0.47 (95% CI, 0.35-0.64), without increased adverse events, absolute difference, 1.0% (95% CI, -2.7 to 4.8). Exploratory analyses provided that early IVF treatment (<= 48 hours) after symptom onset was associated with an ATE, 15.2% (95% CI, 8.6-21.8) to achieve the primary outcome. Conclusions: As compared to standard of care, the administration of IVF in patients with acute hydrocephalus caused by intracerebral and intraventricular hemorrhage was significantly associated with improved functional outcome at 6 months. T

Published
2022

28. Association of intraventricular fibrinolysis with clinical outcomes in intracerebral hemorrhage: an individual participant data meta-analysis

Author

Kuramatsu, Joji B, Gerner, Stefan T, Falcone, Guido J, Selim, Magdy H, Lioutas, Vasileios-Arsenios, Endres, Matthias, Zweynert, Sarah, Vajkoczy, Peter, Ringleb, Peter A, Purrucker, Jan C, Volkmann, Jens, Neugebauer, Hermann, Ziai, Wendy, Erbguth, Frank, Schellinger, Peter D, Knappe, Ulrich J, Fink, Gereon R, Dohmen, Christian, Minnerup, Jens, Reichmann, Heinz, Schneider, Hauke, Röther, Joachim, Reimann, Gernot, Bardutzky, Jürgen, Schwarz, Michael, Bäzner, Hansjörg, Claßen, Joseph, Michalski, Dominik, Witte, Otto W, Günther, Albrecht, Hamann, Gerhard F, Lücking, Hannes, Dörfler, Arnd, Ishfaq, Muhammad Fawad, Sembill, Jochen A, Chang, Jason J, Testai, Fernando D, Woo, Daniel, Alexandrov, Andrei V, Staykov, Dimitre, Goyal, Nitin, Tsivgoulis, Georgios, Sheth, Kevin N, Awad, Issam A, Schwab, Stefan, Sprügel, Maximilian I, Hanley, Daniel F, Huttner, Hagen B, Collaborators, Sansing, Lauren, Matouk, Charles C, Leasure, Audrey, Sobesky, Jan, Bauer, Miriam, Schurig, Johannes, Rizos, Timolaos, Mrochen, Anne, Haeusler, Karl Georg, Müllges, Wolfgang, Kraft, Peter, Schubert, Anna-Lena, Stösser, Sebastian, Ludolph, Albert, Nueckel, Martin, Glahn, Jörg, Stetefeld, Henning, Rahmig, Jan, Kölbl, Kathrin, Fisse, Anna Lena, Michels, Peter, Schwert, Henning, Hagemann, Georg, Rakers, Florian, Wöhrle, Johannes C, Alshammari, Fahid, Horn, Markus, Bahner, Dirk, Urbanek, Christian, Ram, Malathi, Palm, Frederick, Grau, Armin, and Avadhani, Radhika

Subjects
Advanced and Specialized Nursing, drug therapy [Cerebral Hemorrhage], Fibrinolysis, diagnostic imaging [Cerebral Hemorrhage], intracerebral hemorrhage, mortality, Observational Studies as Topic, Treatment Outcome, Fibrinolytic Agents, standard of care, Drainage, Humans, Neurology (clinical), methods [Drainage], ddc:610, Cardiology and Cardiovascular Medicine, hydrocephalus, Cerebral Hemorrhage, Hydrocephalus
Abstract

Background: In patients with intracerebral hemorrhage (ICH), the presence of intraventricular hemorrhage constitutes a promising therapeutic target. Intraventricular fibrinolysis (IVF) reduces mortality, yet impact on functional disability remains unclear. Thus, we aimed to determine the influence of IVF on functional outcomes. Methods: This individual participant data meta-analysis pooled 1501 patients from 2 randomized trials and 7 observational studies enrolled during 2004 to 2015. We compared IVF versus standard of care (including placebo) in patients treated with external ventricular drainage due to acute hydrocephalus caused by ICH with intraventricular hemorrhage. The primary outcome was functional disability evaluated by the modified Rankin Scale (mRS; range: 0–6, lower scores indicating less disability) at 6 months, dichotomized into mRS score: 0 to 3 versus mRS: 4 to 6. Secondary outcomes included ordinal-shift analysis, all-cause mortality, and intracranial adverse events. Confounding and bias were adjusted by random effects and doubly robust models to calculate odds ratios and absolute treatment effects (ATE). Results: Comparing treatment of 596 with IVF to 905 with standard of care resulted in an ATE to achieve the primary outcome of 9.3% (95% CI, 4.4–14.1). IVF treatment showed a significant shift towards improved outcome across the entire range of mRS estimates, common odds ratio, 1.75 (95% CI, 1.39–2.17), reduced mortality, odds ratio, 0.47 (95% CI, 0.35–0.64), without increased adverse events, absolute difference, 1.0% (95% CI, −2.7 to 4.8). Exploratory analyses provided that early IVF treatment (≤48 hours) after symptom onset was associated with an ATE, 15.2% (95% CI, 8.6–21.8) to achieve the primary outcome. Conclusions: As compared to standard of care, the administration of IVF in patients with acute hydrocephalus caused by intracerebral and intraventricular hemorrhage was significantly associated with improved functional outcome at 6 months. The treatment effect was linked to an early time window

Published
2022

32. A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage

Author

Murthy, Santosh B., primary, Cho, Sung-Min, additional, Gupta, Ajay, additional, Shoamanesh, Ashkan, additional, Navi, Babak B., additional, Avadhani, Radhika, additional, Gruber, Joshua, additional, Li, Yunke, additional, Greige, Tatiana, additional, Lioutas, Vasileios-Arsenios, additional, Norton, Casey, additional, Zhang, Cenai, additional, Mandava, Pitchaiah, additional, Iadecola, Costantino, additional, Falcone, Guido J., additional, Sheth, Kevin N., additional, Biffi, Alessandro, additional, Rosand, Jonathan, additional, Qureshi, Adnan I., additional, Goldstein, Joshua N., additional, Kidwell, Chelsea, additional, Awad, Issam, additional, Selim, Magdy, additional, Hanley, Daniel F., additional, Woo, Daniel, additional, Kamel, Hooman, additional, and Ziai, Wendy C., additional

Published
2020
Full Text
View/download PDF

33. Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III Trials.

Author

Magid-Bernstein, Jessica R., Li, Yunke, Cho, Sung-Min DO, Piran, Pirouz J., Roh, David J., Gupta, Ajay MS, Shoamanesh, Ashkan, Merkler, Alexander MS, Zhang, Cenai MS, Avadhani, Radhika MS, Montano, Nataly, Iadecola, Constantino, Falcone, Guido J. ScD,, Sheth, Kevin N., Qureshi, Adnan I., Rosand, Jonathan, Goldstein, Joshua, Awad, Issam, Hanley, Daniel F., and Kamel, Hooman MS

Published
2022
Full Text
View/download PDF

34. Abstract 17: An Evaluation of Patient Disposition and Long-term Health-related Quality of Life In MISTIE III: Opportunities to Improve Decision Making for Critically Ill Intracerebral Hemorrhage Patients

Author

Carhuapoma, Lourdes, primary, Avadhani, Radhika, additional, Ostapkovich, Noeleen, additional, Lane, Karen, additional, McBee, Nichol, additional, Carhuapoma, Juan R, additional, Ziai, Wendy, additional, Awad, Issam, additional, Thompson, Richard E, additional, and Hanley, Daniel F, additional

Published
2020
Full Text
View/download PDF

35. Abstract 18: Diffusion Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage: A Pooled Analysis of Individual Patient Data From MISTIE-III, ATACH-II, I-DEF, and ERICH

Author

Murthy, Santosh B, primary, Cho, Sung-Min, additional, Gupta, Ajay, additional, Shoamanesh, Ashkan, additional, Avadhani, Radhika, additional, Gruber, Joshua, additional, Greige, Tatiana, additional, Lioutas, Vasileios-Arsenios, additional, Norton, Casey, additional, Mandava, Pitchaiah, additional, Falcone, Guido J, additional, Sheth, Kevin N, additional, Qureshi, Adnan I, additional, Goldstein, Joshua N, additional, Kidwell, Chelsea, additional, Selim, Magdy, additional, Woo, Daniel, additional, Kamel, Hooman, additional, Ziai, Wendy C, additional, and Hanley, Daniel F, additional

Published
2020
Full Text
View/download PDF

40. African American Screening and Enrollment in (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage III) CLEAR III

Author

Lane, Karen, Keita, Maningbe, Avadhani, Radhika, Dlugash, Rachel, Mayo, Steven, Thompson, Richard E, Awad, Issam, McBee, Nichol, Ziai, Wendy, and Hanley, Daniel F

Subjects
Article
Abstract

Under-enrolling minority patients in clinical trials reduces generalizability. CLEAR III, a randomized controlled trial, presented an opportunity to assess African American (AA) participation.AA enrollment was compared to U.S. population and NINDS trial data then stratified by region; census data for 42 recruitment cities were compared to screening and randomization percentages, using simple linear regression.AAs were 25% of screens and 45.1% of enrollments (n=370), more than twice the 19.8% participation rate reported by the 2011 NINDS Advisory Panel on Health Disparities Research and triple the projected 13.9% 2014 U.S. population. Conversion rates were (AA vs. non-AA): overall (8.7% vs. 3.4%, p0.001); Northeast (7.7% vs. 2.9%, p0.001); South (8.2% vs. 4.0%, p0.001); Midwest (10.3% vs. 3.6%, p0.01); and West (8.9% vs. 3.8%, p=0.02). AA enrollments ranged from 0% to 100% (mean: 40.4%). AA screening ranged from 0% to 63.7% (mean: 23.2%). AA city census ranged from 1.3% to 82.7% (mean: 28.0%); higher census was associated with higher screening (p0.0001) and enrollment (p=0.004).AAs were willing to enroll in an acute stroke trial. AA city census rates should be considered when selecting enrollment centers and setting recruitment goals. Factors leading to successful AA recruitment should be further investigated, as population-based participation is a goal in all trials.

Published
2018

42. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial

Author

Hanley, Daniel F, primary, Thompson, Richard E, additional, Rosenblum, Michael, additional, Yenokyan, Gayane, additional, Lane, Karen, additional, McBee, Nichol, additional, Mayo, Steven W, additional, Bistran-Hall, Amanda J, additional, Gandhi, Dheeraj, additional, Mould, W Andrew, additional, Ullman, Natalie, additional, Ali, Hasan, additional, Carhuapoma, J Ricardo, additional, Kase, Carlos S, additional, Lees, Kennedy R, additional, Dawson, Jesse, additional, Wilson, Alastair, additional, Betz, Joshua F, additional, Sugar, Elizabeth A, additional, Hao, Yi, additional, Avadhani, Radhika, additional, Caron, Jean-Louis, additional, Harrigan, Mark R, additional, Carlson, Andrew P, additional, Bulters, Diederik, additional, LeDoux, David, additional, Huang, Judy, additional, Cobb, Cully, additional, Gupta, Gaurav, additional, Kitagawa, Ryan, additional, Chicoine, Michael R, additional, Patel, Hiren, additional, Dodd, Robert, additional, Camarata, Paul J, additional, Wolfe, Stacey, additional, Stadnik, Agnieszka, additional, Money, P Lynn, additional, Mitchell, Patrick, additional, Sarabia, Rosario, additional, Harnof, Sagi, additional, Barzo, Pal, additional, Unterberg, Andreas, additional, Teitelbaum, Jeanne S, additional, Wang, Weimin, additional, Anderson, Craig S, additional, Mendelow, A David, additional, Gregson, Barbara, additional, Janis, Scott, additional, Vespa, Paul, additional, Ziai, Wendy, additional, Zuccarello, Mario, additional, Awad, Issam A, additional, Abdul-Rahim, Azmil, additional, Abou-Hamden, Amal, additional, Abraham, Michael, additional, Ahmed, Azam, additional, Alba, Carlos Alarcon, additional, Aldrich, E. Francois, additional, Altschul, David, additional, Amin-Hanjani, Sepideh, additional, Anderson, Doug, additional, Ansari, Safdar, additional, Antezana, David, additional, Ardelt, Agnieszka, additional, Arikan, Fuat, additional, Baguena, Marcelino, additional, Baker, Alexandra, additional, Barrer, Steven J., additional, Becker, Kyra J., additional, Bergman, Thomas, additional, Boström, Azize, additional, Braun, Jamie, additional, Brindley, Peter, additional, Broaddus, William C., additional, Brown, Robert, additional, Buki, Andras, additional, Cao, Bing, additional, Cao, Ying, additional, Carrion-Penagos, Julian, additional, Chalela, Julio, additional, Chang, Tiffany, additional, Chorro, Indalecio Moran, additional, Chowdhry, Shakeel, additional, Corral, Luisa, additional, Csiba, Laszlo, additional, Davies, Jason, additional, Díaz, Alberto Torres, additional, Derdeyn, Colin P., additional, Diringer, Michael, additional, Dlugash, Rachel, additional, Ecker, Robert, additional, Economas, Tracey, additional, Enriquez, Pedro, additional, Ezer, Erzsebet, additional, Fan, Yuhua, additional, Feng, Hua, additional, Franz, Douglas, additional, Freeman, W. David, additional, Fusco, Matthew, additional, Galicich, Walter, additional, Gelea, Mary Leigh, additional, Goldstein, Joshua, additional, Gonzalez, Alejandro Carrasco, additional, Grabarits, Christina, additional, Greenberg, Steven, additional, Gress, Daryl, additional, Gu, Eugene, additional, Hall, Christiana, additional, Hernandez, Fernando Muñoz, additional, Hoesch, Robert, additional, Hoh, Brian L., additional, Houser, Jennifer, additional, Hu, Rong, additional, Huang, Yi, additional, Hussain, Mohammed Akbar, additional, Insinga, Salvatore, additional, Jadhav, Ashutosh, additional, Jaffe, Jennifer, additional, Jahromi, Babak S., additional, Jallo, Jack, additional, James, Michael, additional, James, Robert F., additional, Jankowitz, Brian, additional, Jeon, Esther, additional, Jichici, Draga, additional, Jonczak, Karin, additional, Jonker, Ben, additional, Karlen, Nicki, additional, Keric, Naureen, additional, Kerz, Thomas, additional, Knopman, Jared, additional, Koenig, Carolyn, additional, Krishnamurthy, Satish, additional, Kumar, Avinash, additional, Kureshi, Inam, additional, Laidlaw, John, additional, Lakhanpal, Arun, additional, Latorre, Julius Gene, additional, Leifer, Dana, additional, Leiphart, James, additional, Lenington, Sarah, additional, Li, Yunke, additional, Lopez, George, additional, Lovick, Darren, additional, Lumenta, Christianto, additional, Luo, Jinbiao, additional, Maas, Matthew B., additional, MacDonald, Joel, additional, MacKenzie, Larami, additional, Madan, Vikram, additional, Majkowski, Ryan, additional, Major, Otto, additional, Malhorta, Rishi, additional, Malkoff, Marc, additional, Mangat, Halinder, additional, Maswadeh, Ahmed, additional, Matouk, Charles, additional, McArthur, Kate, additional, McCaul, Scott, additional, Medow, Joshua, additional, Mezey, Geza, additional, Mighty, Janet, additional, Miller, David, additional, Mohan, Krishna K., additional, Muir, Keith, additional, Muñoz, Lorenzo, additional, Nakaji, Peter, additional, Nee, Alex, additional, Nekoovaght-Tak, Saman, additional, Nyquist, Paul, additional, O'Kane, Roddy, additional, Okasha, Mohamed, additional, O'Kelly, Cian, additional, Ostapkovich, Noeleen, additional, Pandey, Aditya, additional, Parry-Jones, Adrian, additional, Perla, Krissia Rivera, additional, Pollack, Ania, additional, Polster, Sean, additional, Pouratian, Nader, additional, Quinn, Terry, additional, Rajajee, Ventatakrishna, additional, Reddy, Kesava, additional, Rehman, Mohammed, additional, Reimer, Ronald, additional, Rincon, Fred, additional, Rybinnik, Igor, additional, Sanchez, Baltasar, additional, Sansing, Lauren, additional, Schneck, Michael, additional, Schuerer, Ludwig, additional, Schul, David, additional, Schweitzer, Jeffrey, additional, Seder, David B., additional, Seyfried, Donald, additional, Sheth, Kevin, additional, Spiotta, Alejandro, additional, Stechison, Michael, additional, Szabo, Katalin, additional, Tamayo, Gonzalo, additional, Tanczos, Krisztian, additional, Taussky, Philipp, additional, Terry, John, additional, Testai, Fernando, additional, Thomas, Kathrine, additional, Thompson, Carol B., additional, Thompson, Gregory, additional, Torner, James C., additional, Tran, Huy, additional, Tucker, Kristi, additional, Ungar, Lior, additional, Varelas, Panos, additional, Vargas, Nataly Montano, additional, Vatter, Hartmut, additional, Venkatasubramanian, Chitra, additional, Vermillion, Krista, additional, Vollmer, Dennis, additional, Wang, Yan, additional, Wang, Ying, additional, Wen, Jiajun, additional, Whitworth, Louis Tony, additional, Willis, Byron, additional, Wrencher, Myriha, additional, Wright, Shawn E., additional, Xu, Yongge, additional, Yanase, Lisa, additional, Yi, Xuxia, additional, Yu, Zhiyuan, additional, and Zomorodi, Ali, additional

Published
2019
Full Text
View/download PDF

45. Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease

Author

Casella, James F, primary, Adams, Robert J, additional, Brambilla, Donald J, additional, Strouse, John J, additional, Maier, Pia, additional, Dlugash, Rachel, additional, Avadhani, Radhika, additional, Vermillion, Krista, additional, Tonascia, James, additional, Voeks, Jenifer H, additional, Hanley, Daniel F, additional, Thompson, Richard E, additional, and Lehmann, Harold P, additional

Published
2018
Full Text
View/download PDF

46. Good Extended Glasgow Coma Scale Predicts Normal Cognition Function Status Among Hemorrhage Stroke Survivors : Clear Iii and Mistie Iii Trials Results

Author

Avadhani, Radhika

Abstract

Introduction: Good functional outcome, measured by extended Glasgow Coma Scale (GOSE) scores assessed at day 30 were examined whether it could predict normal cognition function, measured by Mini-Mental State Examination (MMSE) at day 365. Methodology: 732 survivors in the MISTIE III and CLEAR III trials were analyzed. The patients were followed for one-year with MMSE and GOSE collected at day 30 (D30), 180 (D180) and 365 (D365). Good GOSE was defined as 4-8 and normal MMSE >=24. Multivariate logistic regression (MLR) was used to estimate the relationship between good D30 GOSE and normal D365 MMSE, adjusting for age, any ICH location, ICH hemisphere and total blood burden, measured as stability ICH plus IVH. Results: The odds of normal D365 MMSE were almost 3 times higher for patients with good D30 GOSE as compared those with poor D30 GOSE (OR [95% CI] = 3.65 [2.12, 6.31]). In MLR model, D30 good GOSE (AOR [95% CI] = 2.29 [1.25, 4.21], p=0.007), age (AOR [95% CI] = 0.96 [0.94, 0.98], p

Published
2017

47. Relationship of White Matter Lesions with Intracerebral Hemorrhage Expansion and Functional Outcome: MISTIE II and CLEAR III.

Author

Hansen, Björn M., Ullman, Natalie, Muschelli, John, Norrving, Bo, Dlugash, Rachel, Avadhani, Radhika, Awad, Issam, Zuccarello, Mario, Ziai, Wendy C., Hanley, Daniel F., Thompson, Richard E., and Lindgren, Arne

Subjects
CEREBRAL hemorrhage, CLINICAL trial registries, CEREBRAL small vessel diseases, INTRAVENTRICULAR hemorrhage, RANDOMIZED controlled trials
Abstract

Background/Objective: Intracerebral hemorrhage (ICH) patients commonly have concomitant white matter lesions (WML) which may be associated with poor outcome. We studied if WML affects hematoma expansion (HE) and post-stroke functional outcome in a post hoc analysis of patients from randomized controlled trials. Methods: In ICH patients from the clinical trials MISTIE II and CLEAR III, WML grade on diagnostic computed tomography (dCT) scan (dCT, < 24 h after ictus) was assessed using the van Swieten scale (vSS, range 0–4). The primary outcome for HE was > 33% or > 6 mL ICH volume increase from dCT to the last pre-randomization CT (< 72 h of dCT). Secondary HE outcomes were: absolute ICH expansion, > 10.4 mL total clot volume increase, and a subgroup analysis including patients with dCT < 6 h after ictus using the primary HE definition of > 33% or > 6 mL ICH volume increase. Poor functional outcome was assessed at 180 days and defined as modified Rankin Scale (mRS) ≥ 4, with ordinal mRS as a secondary endpoint. Results: Of 635 patients, 55% had WML grade 1–4 at dCT (median 2.2 h from ictus) and 13% had subsequent HE. WML at dCT did not increase the odds for primary or secondary HE endpoints (P ≥ 0.05) after adjustment for ICH volume, intraventricular hemorrhage volume, warfarin/INR > 1.5, ictus to dCT time in hours, age, diabetes mellitus, and thalamic ICH location. WML increased the odds for having poor functional outcome (mRS ≥ 4) in univariate analyses (vSS 4; OR 4.16; 95% CI 2.54–6.83; P < 0.001) which persisted in multivariable analyses after adjustment for HE and other outcome risk factors. Conclusions: Concomitant WML does not increase the odds for HE in patients with ICH but increases the odds for poor functional outcome. Clinical Trial Registration: http://www.clinicaltrials.gov trial-identifiers: NCT00224770 and NCT00784134. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

49. Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease.

Author

Casella, James F., Adams, Robert J., Brambilla, Donald J., Strouse, John J., Maier, Pia, Dlugash, Rachel, Avadhani, Radhika, Vermillion, Krista, Tonascia, James, Voeks, Jenifer H., Hanley, Daniel F., Thompson, Richard E., and Lehmann, Harold P.

Subjects
DRUG therapy for sickle cell anemia, NEUROLOGICAL disorder prevention, HYDROXYUREA, CLINICAL trials, HEALTH attitudes, MEDICAL research, HEALTH outcome assessment, SICKLE cell anemia, EVIDENCE-based medicine, DISEASE complications, CHILDREN, THERAPEUTICS
Abstract

Background Studies of interventions to prevent the many neurological complications of sickle cell disease must take into account multiple outcomes of variable severity, with limited sample size. The goals of the studies presented were to use investigator preferences across outcomes to determine an attitude-based weighting of relevant clinical outcomes and to establish a valid composite outcome for a clinical trial. Methods In Study 1, investigators were surveyed about their practice regarding hydroxyurea therapy and opinions about outcomes for the "Hydroxyurea to Prevent the Central Nervous System Complications of Sickle Cell Disease Trial" (HU Prevent), and their minimally acceptable relative risk reduction for the two outcome components, motor and neurocognitive deficits. In Study 2, HU Prevent investigators provided overall weights for these two components. In Study 3, they provided more granular rankings, ratings, and maximum number acceptable to harm. A weighted composite outcome, the Stroke Consequences Risk Score, was constructed that incorporates the major neurologic complications of sickle cell disease. The Stroke Consequences Risk Score represents the 3-year risk of suffering the adverse consequences of stroke. In Study 4, the results of the Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP2) and Silent Infarct Transfusion Trials were reanalyzed in light of the composite outcome. Results In total, 22 to 27 investigators participated per study. In Study 1, across three samplings between 2009 and 2015, the average minimally acceptable relative risk reduction ranged from 0.36 to 0.50, at or below the target effect size of 0.50. In 2015, 21 (91%) reported that a placebo-controlled trial is reasonable; 23 (100%), that it is ethical; and 22 (96%), that they would change their practice, if the results of the trial were positive. In Studies 2 and 3, the weight elicited for a cognitive decline (of 10 IQ points) from the overall assessment was 0.67 (and for motor deficit, the complementary 0.33); from ranking, 0.6; from rating, 0.58; and from maximal number acceptable to harm, 0.5. Using data from two major clinical trials, Study 4 demonstrated the same conclusions as the original trials using the Stroke Consequences Risk Score, with smaller p-values for both reanalyses. An assessment of acceptability was performed as well. Conclusion This set of studies provides the rationale, justification, and validation for the use of a weighted composite outcome and confirms the need for the phase III HU Prevent study. Surveys of investigators in multi-center studies can provide the basis of clinically meaningful outcomes that foster the translation of study results into practice while increasing the efficiency of a study. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

50. Fibrinolytic for treatment of intraventricular hemorrhage: A meta-analysis and systematic review.

Author

Baker, Alexandra Delaney, Perla, Krissia Margarita Rivera, Yu, Zhiyuan, Dlugash, Rachel, Avadhani, Radhika, Mould, William Andrew, Ziai, Wendy, Thompson, Richard E, Staykov, Dimitre, and Hanley, Daniel F

Subjects
FIBRINOLYTIC agents, INTRAVENTRICULAR hemorrhage, META-analysis, SYSTEMATIC reviews, MORTALITY, THERAPEUTICS
Abstract

Background: Intraventricular hemorrhage is a significant cause of mortality and morbidity worldwide. Treating intraventricular hemorrhage with intraventricular fibrinolytic therapy via a catheter is becoming an increasingly utilized intervention. Aims: This meta-analysis aimed to investigate the role of intraventricular fibrinolytic treatment in hypertensive intraventricular hemorrhage patients and evaluate the effect sizes for survival as well as level of function at differing time points. Summary of review: PubMed, CNKI, VIP, and Wanfang were searched using the terms "IVH" and "IVH and ICH" for human studies with adult patients published between January 1950 and July 2016. Seventeen publications were selected. Data analysis showed lower rates of mortality in the treatment group at 30 days (P<0.001), 180 days (P = 0.001), 365 days (P = 0.40), and overall (P<0.001). Pooling modified Rankin Scale and Glasgow outcome scale data, the treatment group had more good functional outcomes at 30 days (P = 0.38), 90 days (P = 0.04), 180 days (P = 0.31), 365 days (P = 0.76), and overall (P = 0.02). Good functional outcome was defined as modified Rankin Scale score of 0 to 3 or a Glasgow outcome scale score of 3 to 5. Conclusions: Intraventricular fibrinolytic for treatment of hypertensive intraventricular hemorrhage reduces mortality and potentially leads to an increased number of good functional outcomes. Different functional outcome scales (modified Rankin Scale or Glasgow outcome scale) produce different effect sizes. Intraventricular fibrinolytic treatment may offer intraventricular hemorrhage patients a targeted therapy that produces meaningful mortality benefit and possible functional outcome benefits. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results